Foley Partner John Wilson was quoted in an article that appeared in Agenda on October 11, 2010 titled “No Proxy Access in 2011 as SEC Approves Stay.” Wilson discusses the SEC order agreeing to delay the implementation of proxy access until the D.C. circuit court rules on a lawsuit seeking to overturn the regulation. He states that the order makes sense given the legal implications of moving forward with proxy access only to have it invalidated by the court, but notes that the SEC would likely appeal the decision were the circuit court to overturn the regulation. Wilson adds that companies should be proactive with their shareholders in the event that the SEC moves forward with a modified version of its proxy access rules.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”